Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine: Efficacy of ramosetron in the treatment of IBS male patients
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The 5-HT(3) receptor antagonists are known to be effective for the treatment of diarrhea-predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5-HT(3) receptor antagonist, and mebeverine in male patients with IBS with diarrhea (IBS-D). METHODS: This study was performed in a multicenter, randomized, open-label design. Data of 343 male patients with IBS-D who were randomized to either a 4-week treatment of ramosetron 5μg once daily or a 4-week treatment of mebeverine 135 mg three times daily were analyzed by the intent-to-treat analysis. The primary efficacy parameter was the proportion of patients with adequate relief of IBS symptoms at the last week of treatment. The secondary endpoints were changes in each symptom score and the safety profiles. KEY RESULTS: The responder rates for global IBS symptoms, abdominal pain/discomfort and abnormal bowel habits in the ramosetron and mebeverine groups significantly increased during the treatment period. The severity scores of abdominal pain/discomfort and urgency, the stool form score, and the stool frequency in both treatment arms were significantly reduced, compared with the baselines. There were no significant differences in the responder rates (37%vs 38% on ITT analysis) and adverse event profiles between the ramosetron and mebeverine groups. Neither severe constipation nor ischemic colitis was reported by ramosetron-treated patients. CONCLUSIONS & INFERENCES: Ramosetron 5μg once daily is as effective as mebeverine three times daily in male patients with IBS-D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials
Cremonini, F., Delgado‐Aros, S., & Camilleri, M. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00389.x · Cited by 219
Gwee, K.-A., Wee, S., Wong, M.-L., & J C Png, D. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04161.x · Cited by 190
Cited by
Sex-gender differences in irritable bowel syndrome
Kim, Y. S., & Kim, N. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18082 · Cited by 322
Self-citationBlack, C. J., Burr, N. E., Camilleri, M., Earnest, D. L., Quigley, E. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2018-318160 · Cited by 191
Black, C. J., Yuan, Y., Selinger, C. P., Camilleri, M., Quigley, E. M. M., Moayyedi, P., & Ford, A. C. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30324-3 · Cited by 171
Fukudo, S., Kinoshita, Y., Okumura, T., Ida, M., Akiho, H., Nakashima, Y., Nishida, A., & Haruma, K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.047 · Cited by 125
Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition
Song, K. H., Jung, H.-K., Kim, H. J., Koo, H. S., Kwon, Y. H., Shin, H. D., Lim, H. C., Shin, J. E., Kim, S. E., Cho, D. H., et al. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17145 · Cited by 47
Metadata
- Authors
- Lee, K. J., Kim, N. Y., Kwon, J. K., Huh, K. C., Lee, O. Y., Lee, J. S., Choi, S. C., Sohn, C. I., Myung, S. J., Park, H. J., Choi, M. K., Bak, Y. T., & Rhee, P. L.
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2011-09-15
- Volume
- 23
- Issue
- 12
- Pages
- 1098-1104
- ISSN
- 1350-1925 (ISSN-L)
- OpenAlex
- W1901791757
- Cited by
- 71
- References
- 3
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine: Efficacy of ramosetron in the treatment of IBS male patients. https://app.cochat.ai/papers/10.1111/j.1365-2982.2011.01771.x
- The paper
- Lee, K. J., Kim, N. Y., Kwon, J. K., Huh, K. C., Lee, O. Y., Lee, J. S., Choi, S. C., Sohn, C. I., Myung, S. J., Park, H. J., Choi, M. K., Bak, Y. T., & Rhee, P. L. (2011). Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine: Efficacy of ramosetron in the treatment of IBS male patients. Neurogastroenterology & Motility. https://doi.org/10.1111/j.1365-2982.2011.01771.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.